Company Overview - IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases [3] - The company's lead program, INB-100, targets acute myeloid leukemia using haplo-matched allogeneic γδ T cells post-hematopoietic stem cell transplant [3] - IN8bio is also advancing autologous DeltEx DRI γδ T cells for glioblastoma in its INB-200 and INB-400 programs, along with INB-600, which focuses on novel γδ T cell engagers for oncology and autoimmune indications [3] Conference Participation - William Ho, CEO and co-founder of IN8bio, will present at the Noble Emerging Growth Virtual Equity Conference on February 5, 2026, at 3:00 p.m. ET [1] - The company will also participate in the IO360° Conference on February 12, 2026, where it will present on its DeltEx Drug Resistant Immunotherapy (DRI) approach to solid tumors and share results from a Phase 1/2 study in newly diagnosed glioblastoma [2]

Core Insights - Anavex Life Sciences Corp. will release its financial results for the first quarter of fiscal 2026 on February 9, 2026, at 8:30 am ET [1] - A conference call will be held on the same day to review financial results and discuss recent corporate developments, followed by a Q&A session [2] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome [4] - The company's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and has shown potential in treating other CNS disorders [4] - ANAVEX®3-71 is another promising drug candidate targeting SIGMAR1 and M1 muscarinic receptors, demonstrating disease-modifying activity against Alzheimer's disease in preclinical trials [4]

Core Viewpoint - Invivyd, Inc. has received guidance from the U.S. FDA regarding the LIBERTY Phase 3 clinical trial for VYD2311, a monoclonal antibody candidate aimed at preventing COVID-19, which will compare its safety and immunologic profile against mRNA COVID vaccines [1][2][5] Group 1: LIBERTY Trial Overview - The LIBERTY trial will assess the safety and immunologic profile of VYD2311 compared to commercially available mRNA COVID vaccines, including the simultaneous administration of both [1][5] - The trial is designed to provide insights into the safety and tolerability of monoclonal antibody-mediated prophylaxis versus mRNA vaccines, building on the previous DECLARATION trial [2][5] - Total enrollment for the LIBERTY trial is expected to be around 210 participants [7] Group 2: Background on VYD2311 - VYD2311 is a novel monoclonal antibody candidate developed to address the need for new COVID-19 prevention options, with a focus on delivering effective titer levels through intramuscular administration [4][6] - The antibody was engineered using Invivyd's proprietary technology platform, optimized for neutralizing contemporary virus lineages [6] Group 3: Regulatory Context and Safety Monitoring - The FDA has requested specific monitoring for adverse events of special interest, particularly myocarditis and pericarditis, in the LIBERTY trial due to concerns raised during the COVID pandemic regarding mRNA vaccines [2][5] - No similar monitoring requests have been made for other Invivyd trials that do not include an mRNA vaccine arm [2][5] Group 4: DECLARATION Trial Details - The DECLARATION trial is a Phase 3, randomized, triple-blind, placebo-controlled study evaluating the efficacy and safety of VYD2311 in preventing symptomatic COVID-19, with an expected enrollment of 1770 participants [3][8] - Participants will receive either a single or monthly dose of VYD2311 via intramuscular injection, compared to a placebo [3][8]

Core Insights - LeonaBio, Inc. has appointed Mark F. Kubik as Chief Business Officer to lead its business development strategy, focusing on licensing, partnership strategy, and corporate development initiatives [1][3] Company Overview - LeonaBio is a clinical-stage biopharmaceutical company based in Bothell, Washington, dedicated to developing novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS) [10] Leadership Appointment - Mark F. Kubik brings over 25 years of biopharma business development and corporate strategy experience, having previously served as a strategic consultant to LeonaBio [2][4] - His appointment is seen as pivotal for advancing the Phase 3 development of lasofoxifene for metastatic breast cancer and building a diversified pipeline in oncology and neurodegeneration [3] Strategic Vision - Mr. Kubik expressed excitement about joining LeonaBio at a critical juncture, emphasizing the urgency of advancing lasofoxifene as a therapeutic candidate for treatment-resistant metastatic breast cancer [3] - The company aims to expand its portfolio and explore strategic collaborations under his leadership [3] Inducement Stock Option - LeonaBio announced an equity inducement award to Mr. Kubik, granting him stock options to purchase 30,000 shares at an exercise price of $4.74, effective from February 1, 2026 [6][7] - The vesting schedule includes one-fourth of the shares vesting on the first anniversary and one forty-eighth each month thereafter, contingent on continued service [8] Educational Background - Mr. Kubik holds an MBA in Finance and a BA in Molecular, Cellular and Developmental Biology from the University of Colorado, Boulder, and has completed Executive Education in Negotiation and Influence Strategies at Stanford University [5]

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first quarter of fiscal 2026 ended November 30, 2025 (Q1:2026) and provided an update on operational progress for the quarter. ...

Cardiac dosing limit removed and path forward to dose selection identifiedLONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosin ...

Core Insights - The FDA has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for treating adults with PIK3CA mutant, HR+/HER2- locally advanced or metastatic breast cancer [1][2][3] Group 1: Clinical Data and Trials - The Breakthrough Therapy designation is supported by clinical data from the Phase 1/2 ReDiscover trial, which evaluated zovegalisib's safety, tolerability, pharmacokinetics, and preliminary antitumor activity [3][4] - Initial Phase 1/2 data for zovegalisib + fulvestrant at the 400mg BID fed dose will be presented at the ESMO Targeted Anticancer Therapies Congress on March 16, 2026 [1][4] - The ReDiscover trial included data from two doses: 600mg BID fasted (N=52) and 400mg BID fed (N=57), with the latter being the dose used in the ongoing Phase 3 trial [3] Group 2: Market Potential and Patient Impact - Approximately 40% of patients with HR+/HER2- advanced breast cancer have PIK3CA mutations, leading to limited treatment options after CDK4/6 inhibitors [2][8] - Zovegalisib has the potential to address a significant portion of the estimated 140,000 patients with HR+, HER2- breast cancer with a PI3Kα mutation annually in the U.S. [5] Group 3: Mechanism and Innovation - Zovegalisib is the first known allosteric, pan-mutant, and isoform-selective PI3Kα inhibitor, designed to overcome limitations of traditional PI3Kα inhibitors [6] - The development of zovegalisib utilized advanced computational methods to elucidate conformational differences between wild-type and mutant PI3Kα [6]

Core Insights - Axsome Therapeutics Inc. (NASDAQ:AXSM) is recognized as a promising mid-cap stock by leading investors, with H.C. Wainwright raising its price target from $200 to $260 while maintaining a Buy rating [1] - The company reported interim unaudited financial results for Q4 2025, projecting total product revenue of approximately $196 million [1] Revenue Projections - Axsome anticipates overall product revenue of around $638.5 million for fiscal year 2025, representing a 66% increase compared to fiscal year 2024, surpassing H.C. Wainwright's estimate of $628.3 million [2] - The primary product, AUVELITY, is expected to generate net sales of about $155.1 million in Q4 and $507.1 million for the full year 2025, significantly exceeding the firm's annual sales estimate of $397 million [2] Performance of Other Products - Other products, such as SUNOSI, are also projected to perform well, with expected revenues of $36.7 million in Q4 and $124.8 million for the entire year [3] - Axsome Therapeutics focuses on developing novel therapies for central nervous system (CNS) disorders in the US [3]

Group 1 - Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is recognized as a mid-cap stock to buy, with Truist Securities raising its price target to $230 from $220 while maintaining a Buy rating [1] - The increase in price target is attributed to positive results from the HERIZON-GEA trial, leading to higher estimations for Ziihera [1][3] - Jazz Pharmaceuticals plans to file a supplemental Biologics License Application (sBLA) in the first half of 2026 to obtain a broad label for first-line gastroesophageal adenocarcinoma (GEA) as both doublet and triplet therapy [2] Group 2 - Truist Securities expects strong commercial adoption of Jazz Pharmaceuticals' products following clearance based on clinical data, with over 90% prescriber crossover between GEA and biliary tract cancer (BTC) [3] - The company develops treatments for serious illnesses, with key products including Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos [3]

While reporting financial results for the fourth quarter on Tuesday, biopharmaceutical company Merck & Co., Inc. (MRK), known as MSD outside the U.S. and Canada, initiated its adjusted earnings and net sales guidance for the full-year 2026.For fiscal 2026, Merck now projects adjusted earnings in a range of $5.00 to $5.15 per share on sales between $65.5 billion and $67.0 billion.On average, analysts polled expect the company to report earnings of $5.63 per share on sales of $67.58 billion for the year. Ana ...